IPO Update: 28 Biopharma Companies Raise $3bn, Provide An Average 10% Return

Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.